MedTrace Logo

Study of Alpha-2 Adrenergic Receptor Dysfunction in Regional Lipoatrophy

NCT00004329 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 12

Last updated 2005-06-24

No results posted yet for this study

Summary

OBJECTIVES: I. Determine the response in plasma norepinephrine concentration and plasma glycerol to the agonist (clonidine) and the antagonist (yohimbine) of the alpha-2 adrenergic receptor in 6 patients with regional lipoatrophy and in 6 controls.

II. Determine the full sequence of the alpha-2 adrenergic receptor structural gene in genomic DNA from peripheral blood leukocytes.

Conditions

  • Lipodystrophy

Sponsors & Collaborators

  • University of Texas

    collaborator OTHER

  • National Center for Research Resources (NCRR)

    lead NIH

Principal Investigators

  • Fannie Smith · University of Texas

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
FEMALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
1999-11-30

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00004329 on ClinicalTrials.gov